Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 2/20 | 0.35 |
| ▸ | RARG | P13631 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31429245 | 0.86 | HTR3A (0.43) | HTR3AKMT2AMEN1SSTR4RORC | |
| SCHEMBL31429465 | 0.78 | RAB9A (0.50) | HTR3ARAB9AMAPTKMT2AMEN1 | |
| SCHEMBL1051547 | 0.78 | PTGER4 (0.51) | PTGDR2RORC | |
| SCHEMBL29805363 | 0.77 | HTR3A (0.55) | HTR3ARAB9AKMT2AMEN1TSHR | |
| SCHEMBL8320853 | 0.75 | NAMPT (0.40) | HTR3AMAPTKMT2AMEN1USP2 | |
| SCHEMBL12952106 | 0.74 | CYP1A2 (0.45) | RAB9AMAPTKMT2AMEN1TSHR | |
| SCHEMBL31429212 | 0.74 | RORC (0.40) | HTR3ARAB9AMAPTTSHRRORC | |
| SCHEMBL31429450 | 0.73 | RAB9A (0.45) | HTR3ARAB9AMAPTKMT2AMEN1 | |
| SCHEMBL31429194 | 0.73 | KDM4C (0.46) | HTR3ARAB9AMAPTKMT2AMEN1 | |
| SCHEMBL1051125 | 0.73 | CYP1A2 (0.54) | TSHRSLC22A12PTGDR2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092014-A1 | COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE | METREA BIOSCIENCES INC (US) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092014-A1 | COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE | LPL, LIPA, PNLIP | HTR3A 2975/4885RAB9A 3037/4885MAPT 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.